Brief: Context Therapeutics Says First Patient Dosed In The Phase 1 Clinical Trial Of CTIM-76
14/01/2025 23:01
Jan 14 (Reuters) - Context Therapeutics CNTX.O :
* CONTEXT THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE
PHASE
1 CLINICAL TRIAL OF CTIM-76
* CONTEXT THERAPEUTICS INC - INITIAL DATA FOR CTIM-76 PHASE
1
TRIAL EXPECTED IN H1 2026
Source text: ID:nGNX2kRNDp
Further company coverage: CNTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202